USPTO Patents Application 09639859

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of
the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

• BLACK BORDERS

• TEXT CUT OFF AT TOP, BOTTOM OR SIDES

• FADED TEXT

• ILLEGIBLE TEXT

• SKEWED/SLANTED IMAGES

• COLORED PHOTOS

• BLACK OR VERY BLACK AND WHITE DARK PHOTOS

• GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images,
please do not report the images to the
Image Problem Mailbox.

\

VD

CO

00

w

CO

t- 1

00

to

o
in

CD
CO

H 1

CO

oo

CO

o

in

dd

CO

tr 1
in

oo CO
to

CO

tr 1

o

H
I— 1
(— 1

dd

CO

tr"
u>

ID

00

CO

CD

CO

CO

CO

in

dd

CO

CO

in

(D

X
H-
rt

CTi
0)

s

oo

o
o

I

o

ft —
(D tr

h{ 0)
p hj

H-(D 0)

rr C
h- rr
O H-
3 O

O
CD

rr

— H-
O

CL I — 1

o

CO

3
CD

in ^

CO

0

co

3

CD

3 o

cd

rr to
tr rr
CD

CO

3

CD

O
H-

CD
O

0) O
H- CO

2 rr
CD H-

CD

O I — 1 tQ
^ CD M
C ^
rr o o
tr h- h-
^ p p

CD CD CD

O

H-

CD

O
4

H- £>
CO h- 1
O 0>

CD H-
C 3
O CD
H-

3 O
CD h|

P>
3

H-

o

1 — 1 CQ *Q

h- m tr
>d o

O O CQ
tJ O t3

m m tr
o h- o

rr ^ I— 1
CD H- H-

o

ri

o ^

rr o
CD O
O V

[Q hi

m O
^ rr
O CD
H-

O

03 o o in

C h o h-
h- 1 I — 1 ^
I — h - — I — 1 o
O 0) o
rr tTCQ 03
CD hi CD 0)
^ O 0 3

o a o t3

ii h M O
O IQ

H- O h-

rr pj ^

H- hj O

3 rr pj

&) I-*

a sd o

LJ-CQ h{
CD

3 CD

Q) X

rr rr
H

H-

ri

X O
CD

H- Qj h- '

o
o

I

o
c

o
o

I

o

03
H-

rr

H-

o
0

CQ
(D
P>
H
O

tr

H

a>

rr

D M CJ
W ^ CO

fd o u
>

td H

o d

- CO
I

Q
dd

a m a

rr| ^ CO

M H

H ^
O

a m c

M co

a m c

M ^ CO
>

W H

o a

- CO
I

nd
o

a

dd

a td cj
m ^ CO
o

CO
I

O
dd

a m c

M ^ CO

SI- >

O

3

a m a

M T3 CO
O ^

a td a

td ^ co
fd o ^

c|

CO
I

nd
Q

a

dd

nd
O

a td a

td ^ co
>

td H

o a

CO

Q
^d
ci
dd

a

dd

Dd

co

oo

CO

o
o

CO

\

H

<t CO

o

M O
I— 1 M

h- 1 h- 1
CO M

<1 CO

o

h- ' O
M CO

CO
O
O

to

H
h- 1

CO
O
O
CO
\
h- 1
h- 1

to
o
o

CO

o

o co
o

H 1 O
h- 1 to
\
O h- 1
^ h->

CO
O
O

to

o

UJ

<i to
o

H» O
H CO

O H>

W h3

fl> n
» 2

rr CD

H- Hi
O H-

td

h
O

h H Cd
ID O h

1 H 1

H 1

h- 1

h- 1

h- 1

H

H 1

1— 1

1— 1

f— 1

1 ^
1

00

Ln

LO

CO

h- 1

o

in

w

W

W

W

tu

rjd

©

rjd

fd

fd

?d

CO

CO

CO

CO

CO

CO

CO

CO

CO

CO

U
/i\

w

tr 1

f

f

f

f

It 1

f

fi

t*

H

H

1— 1

H

i—»

i— i

i— 1

VD

00

^3

U1

u>

to

1— 1

o

It

to

to

I— 1 CT\

I- 1

Ch

o

i— 1

to

o

I— 1

LaJ

Ln

■^j

o

LO

O

X

M

Ln

1 — 1

00

H-

Ln

1— i

ft

O

03

CTi

0 n ^ 3

t3 tJ H

H 1

Ln

3

H-

PJ O O t3

X H- 0 3 H-

hi 0 CO

O

0

3

y ^ CD CD

03

CO

h- 2 3 rf p

03

0 M

03

03

M

3

rt n n

P>

Qj O CD H- CD

P>

£^ ?

03

P>

h- m tr H-

3

3

fD CQ 0 hi

CD l U PJ

3

3

hi

tr o pj o

CD

CD

— 0 PJ X P>

fD

H- CD 3

CD

3

CD

0

H- 03 M H-

CO

h< I H- M

3 *0 CD

CD

0)

0 TJ 0 M

U) Qj

H 1

rt

M

H

a.

c

ft 0 (0 H

Ol

<!

— P> 0

in

0 —

M

H»

LJ.

H* hi t3 H-

W
h(

N PJ P h

hi Oi»d

CO

O H- 0 3

H- Qj ("T

CD CD

hi

hi

P hi

tr

3 LJ. <j

3 *0

PJ

CD

0 H- 0

O 0 H-

(D 0 ft

rr

03

h{ 0 D h|

0 H ft

CL h{ H-

H-

03

hi

(D

PJ H- P>

h- a

0

OJ

0

& M 3

O CD

hi

n
ft

P>

rr

0

rr h{

hi 0

— "

hi

owe

O M cj

O M G

U M C

owe

a m cj

U M C

O M C

a m g

U M G

M ^ CO

M CO

M ^ CO

M >tf CO

W ^ CO

M ^ CO

td 'rJ co

M CO

M CO

W ^ CO

2 ° H

B ° S

2 ° H

# O ^TJ

a- >

2- >

>

s;- >

s:- >

>

s;- >

>

s;- >

S!- >

M H

td t-3

td H

@ r ^

9 r ^

@ r H

M H

3 Ci

3 C_|

Sg C| —

3 C-i —

3 C| —

3 C| —

S C| —

3 C|

3 C|

H U

H ^

O G

o g

o cj

O G

o CJ

o a

o a

O G

O G

O G

a

— CO

CO

CO

CO

CO

^« CO

CO

^» CO

CO

CO

DO
CD

1

TJ

1

i

i

TJ

1

1

TJ

1

Q

Q

Q

O

a

Q

Q

Q

Q

*d

•X)

G

a

a

a

a

a

G

3

w
>■ •

Od

- •

3

00

to

to

to

rjd
-">•

-o to

*o to

to

to

CO

--J to

■^j to

^0 CO

■»0 CO

-*j to

o

o

o

o

o

O

O

o

o

o

H O

H 1 O

M O

h- 1 o

H O

H O

M O

1— 1 o

H O

H 1 o

CO H

H CO

I— 1 to

h- 1 to

h- 1 to

H CO

M tO

H 1 tO

M CO

M CO

h- 1 to

rt h-

\

. , -s^

0) g

U> M

OJ 1— 1

L0 H 1

U» M

UJ M

00 H

CO H

3 a)

CTl f— 1

-»^_

U) H

tO M

\^

O h- 1

O H 1

H

H 1

1— 1

h- 1

H

h- 1

M

M

H

M

n> n

3 0

<"*■ 3

03 g

h- a [J

ft (D 2

H- hh n

0 H- 0

p p n

o

O

O

O

O

O

O

O

O

O

m 0 h

> d his

(FILE 'HOME' ENTERED AT 12:22:03 ON 17 NOV 2002)

FILE "MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA*
ENTERED AT

12:22:32 ON 17 NOV 2002
LI 2800622 S COMPOSITION

L2 23697 S (PHARMACEUTICAL COMPOSITION) OR (THERAPEUTIC
COMPOSITION)

L3 1 1 029 S (EXTRACELLULAR MATRIX) (W) (MATERIAL OR COMPOUND
OR COMPONENT

L4 1 097283 S GLYCOS AMINOGLYC AN OR COLLAGEN OR CARTILAGE OR
(CHRONDROITIN S

L5 758458 S PHOSPHOLIPID OR GLYCOLIPID OR LIPOPROTEIN

L6 2753 1 50 S (AMINO ACID ) OR GLYCINE OR ALANINE OR LEUCINE OR

ISOLEUCINE

L7 0 S L2 (P) (L3 OR L4) (P) L5 (P) L6

L8 256 S LI (P) (L3 OR L4) (P) L5 (P) L6

L9 111 DUPLICATE REMOVE L8 ( 1 45 DUPLICATES REMOVED)

LI 0 0 S L9 (P) (PHARMACEUTICAL OR THERAPEUTIC OR

MEDICAMENT)

Lll 15 SL9(P) TREAT?

L12 0 S (MOLAR RATION) (P) L9

LI 3 1 03 8986 S PENICILLIN OR CAPHALOSPORIN OR CYCLOSPORIN OR
ANTIBIOTIC OR I

L14 6279 S L6 (P) (MOLAR RATIO)

L15 69SL13(P)L14

L16 0 S L15 (P) (L3 OR L4) (P) L5

L17 2126390 S MINERAL OR VITAMIN OR ANTIOXIDANT OR (OMEGA-3 OIL)

OR ZINC OR

L18 5SL9(P)L17

=> log y

FILE 'HOME' ENTERED AT 12:22:03 ON 17 NOV 2002

=> file medline caplus biosis embase scisearch agricola
COST IN U.S. DOLLARS SINCE FILE

ENTRY

FULL ESTIMATED COST 0.21

FILE ' MEDLINE 1 ENTERED AT 12:22:32 ON 17 NOV 2002

FILE 'CAPLUS' ENTERED AT 12:22:32 ON 17 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:22:32 ON 17 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 12:22:32 ON 17 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 12:22:32 ON 17 NOV 2002

COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 12:22:32 ON 17 NOV 2002

=> s composition

LI 2800622 COMPOSITION

=> s (pharmaceutical composition) or (therapeutic composition)

L2 23697 (PHARMACEUTICAL COMPOSITION) OR (THERAPEUTIC COMPOSITION)

=> s (extracellular matrix) (w) (material or compound or component)

L3 11029 (EXTRACELLULAR MATRIX) (W) (MATERIAL OR COMPOUND OR COMPONENT)

=> s glycosaminoglycan or collagen or cartilage or (chrondroitin sulfate) or glycoprotein or prote
L4 1097283 GLYCOSAMINOGLYCAN OR COLLAGEN OR CARTILAGE OR (CHRONDROITIN

SULFATE) OR GLYCOPROTEIN OR PROTEOGLYCAN

=> s phospholipid or glycolipid or lipoprotein

L5 758458 PHOSPHOLIPID OR GLYCOLIPID OR LIPOPROTEIN

=> s (amino acid ) or Glycine or alanine or leucine or isoleucine or threonine or cystiene or cyst
4 FILES SEARCHED. . .

L6 2753150 (AMINO ACID ) OR GLYCINE OR ALANINE OR LEUCINE OR ISOLEUCINE OR

THREONINE OR CYSTIENE OR CYSTINE OR METHIONINE OR SERINE OR
VALINE

= > s 12 (p) (13 or 14) (p) 15 (p) 16

L7 0 L2 (P) (L3 OR L4) (P) L5 (P) L6

=> s 11 (p) (13 or 14) (p) 15 (p) 16

L8 256 LI (P) (L3 OR L4) (P) L5 (P) L6

=> duplicate remove 18

DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/ (N) :n
PROCESSING COMPLETED FOR L8

L9 111 DUPLICATE REMOVE L8 (145 DUPLICATES REMOVED)

=> s 19 (p) (pharmaceutical or therapeutic or medicament)
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED »L66 (P) »
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L68 (P) '

L10 0 L9 (P) (PHARMACEUTICAL OR THERAPEUTIC OR MEDICAMENT)

=> s 19 (p) treat?

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - ' AND ' OPERATOR ASSUMED »L79 (P) TREAT?'

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

TOTAL
SESSION
0.21

FIELD CODE - 'AND' OPERATOR AS^^ID »L81 (P) TREAT?'
Lll 15 L9 (P) TREAT?

=> d 111 1-15 ibib abs

Lll ANSWER 1 OF
ACCESSION NUMBER
DOCUMENT NUMBER:
TITLE :

AUTHOR :

CORPORATE SOURCE:

CONTRACT NUMBER:
SOURCE :

PUB. COUNTRY:
DOCUMENT TYPE
LANGUAGE :
FILE SEGMENT:
ENTRY MONTH:
ENTRY DATE:

AB A major mucin

15 MEDLINE

93228357 MEDLINE
93228357 PubMed ID: 8470904

Purification and characterization of monkey (Macaca
nemestrina) tracheobronchial mucin.

Devaraj H; Griffith J W; Sheykhnazari M; Naziruddin B;
Sachdev G P; Bhavanandan V P

Department of Biological Chemistry, M. S. Hershey Medical
Center, Pennsylvania State University, Hershey 17033.
HL42651 (NHLBI)

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (1993 Apr) 3 02 (1)
285-93 .

Journal code: 0372430. ISSN: 0003-9861.
United States

Journal; Article; (JOURNAL ARTICLE)
English

Priority Journals
199305

Entered STN : 1993 0521
Last Updated on STN: 19930521
Entered Medline: 19930512
***glycoprotein*** was purified from monkey (Macaca
nemestrina) bronchoalveolar lavages by gel filtration, delipidation, and a
series of density gradient centrif ugations in cesium

trif luoroacetate/guanidinium chloride. Lipids noncovalently associated
with the mucin amounted to 24-36% by weight and consisted primarily of

***phospholipids*** and ***glycolipids*** . The mucin preparation was
free of low-molecular-weight protein/ ***glycoprotein*** contaminants,

***glycosaminoglycans*** / ***proteoglycans*** , and nucleic acids. The
weight -average molecular weight and radius of gyration of the mucin in
buffer containing 6 M guanidinium chloride was estimated to be
approximately 1.56 x 10(6) and 100 nm, respectively, by laser light
scattering technique. When the mucin was dissolved in 0.15 M NaCl, a
considerably higher molecular weight of approximately 5.05 x 10(6) and a
larger radius of gyration of approximately 127 nm were observed suggesting
aggregation of the mucin molecules. ***Amino*** ***acid***

***composition*** of the ***glycoprotein*** was characteristic of
mucins with ***threonine*** , ***serine*** , glutamic acid, proline,

★★★glycine*** , and ***alanine*** comprising 63%. The total
carbohydrate content was 71.5% and consisted of GalNAc, GlcNAc, Gal,
sialic acids, and fucose in the molar ratio of 1.0:2.2:2.4:1.4:1.2 with no
detectable mannose. Alkaline borohydride ***treatment*** indicated
that 65% of the *** threonine*** and 27% of the ***serine*** are
substituted by saccharides via GalNAc residues. An antisera produced
against the purified mucin was found to react well with the native and
weakly with the deglycosylated mucins and will be useful for immunoassays.
A second, minor, mucin ***glycoprotein*** obtained during the
purification was also partially characterized.

Lll ANSWER 2 OF
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE :

AUTHOR :

CORPORATE SOURCE:

SOURCE :

PUB. COUNTRY:
DOCUMENT TYPE:
LANGUAGE :
FILE SEGMENT:
ENTRY MONTH:
ENTRY DATE:

15 MEDLINE

89025571 MEDLINE
89025571 PubMed ID: 2460078

A new class of Paramecium surface proteins anchored in the
plasma membrane by a glycosylinositol phospholipid.
Membrane anchor of Paramecium cross -reacting glycoproteins.
Deregnaucourt C; Keller A M; Capdeville Y
Centre de Genet ique Moleculaire, Departement 1, Centre
National de la Recherche Scientif ique, Gif -sur-Yvette ,
France .

BIOCHEMICAL JOURNAL, (1988 Jul 15) 253 (2) 395-400.

Journal code: 2984726R. ISSN: 0264-6021.

ENGLAND: United Kingdom

Journal; Article; (JOURNAL ARTICLE)

English

Priority Journals
198811

Entered STN: 19900308

:^K>n STN: 19960129
-(^Pie: 19881121

iramecia with ethanol or Triton X-100 i

Last Updat^^m STN: 19960129
Entered Mecl

AB ***Treatment*** of paramecia with ethanol or Triton X-KTo solubilizes

a major membrane protein, namely the surface antigen (SAg) , and a set of
glycopeptides in the range 40-60 kDa, which cross-react with the SAg. We
demonstrate that these glycopeptides, called 'cross-reacting

★★★glycoproteins*** ' (CRGs) , are distinct molecules from the SAg. First,
after purification of CRGs from ethanolic extracts of Paramecium
primaurelia expressing the 156G SAg, the ***amino*** ★★★ ac i c i***

***composition*** of a given CRG was found to be different from, and
incompatible with, that of the 156G SAg. Secondly, we showed that the
CRGs, although not immunologically detectable, are present in fractions
containing the myristoylated form of the 156G SAg. The ***treatment***
of these fractions by phosphatidylinositol-specif ic phospholipases C
enables us to reveal the CRGs through the unmasking of two distinct
epitopes. One is the ' cross -reacting determinant' (CRD), initially
described for the variant surface ***glycoproteins*** (VSGs) of
Trypanosoma; the other determinant, called 'det-2355', is specific to the
SAg and to the CRGs. Our results suggest that (1) phosphatidylinositol is
covalently linked to the CRGs and (2) the CRD and the det-2355 are
localized in the same region of the CRGs. We propose that the CRGs are a
new set of surface proteins anchored in the cell membrane of Paramecium
via a glycosylinositol ***phospholipid*** , in the same way as the
SAgs .

Lll ANSWER 3 OF 15 MEDLINE
ACCESSION NUMBER: 86232308 MEDLINE
DOCUMENT NUMBER: 86232308 PubMed ID: 3754957

TITLE: Hydrophobic surfactant-associated protein in whole lung

surfactant and its importance for biophysical activity in
lung surfactant extracts used for replacement therapy.
AUTHOR: Whitsett J A; Ohning B L; Ross G; Meuth J; Weaver T; Holm B

A; Shapiro D L; Notter R H
CONTRACT NUMBER: HL- 00945 (NHLBI)

HL-10124 (NHLBI)
HL-28623 (NHLBI)
+

SOURCE: PEDIATRIC RESEARCH, (1986 May) 20 (5) 460-7.

Journal code: 0100714. ISSN: 0031-3998.
PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; ( JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198606

ENTRY DATE: Entered STN: 19900321

Last Updated on STN: 19970203
Entered Medline: 19860627

AB Hydrophobic protein of 6,000 and 14,00 0 daltons was isolated from

mammalian pulmonary surfactant obtained from canine, human, and bovine
alveolar lavage material. Low molecular weight, hydrophobic,
surfactant-associated protein (SAP), herein referred to as SAP 6-14, was
distinguished from SAP-35, the major ***glycoprotein*** in mammalian
surfactants (the 35,000 dalton ***glycoprotein*** A or apolipoprotein
A) by ***amino*** ***acid*** ***composition*** , peptide

mapping, and by resistance of SAP 6-14 to digestion by endoglycosidase F,
collagenase, trypsin, and other proteases. The ***amino***

***acid*** ***composition*** of SAP 6-14 was found to be highly

enriched in ***leucine*** and other hydrophobic ***amino***

***acids*** . The characteristics of protein isolated from bovine
replacement surfactant extracts utilized for the ***treatment*** of
hyaline membrane disease in humans were also studied. SAP 6-14 isolated
from calf lung surfactant replacement extracts (CLSE) and surf actant-TA
were found to be identical to SAP 6-14 isolated from ether/ethanol
extracts of various mammalian surfactants. By contrast, SAP-3 5, the major
surfactant-associated ***glycoprotein*** of molecular weight = 35,000,
and other higher molecular weight proteins were not detected in
significant quantities in the CLSE or surf actant-TA replacement
surfactants, either by highly sensitive silver stain analysis or by
immunoblot using monospecific antisera generated against bovine SAP-35.
Biophysical studies of the CLSE replacement surfactant containing only SAP
6-14 and native ***phospholipids*** demonstrated full surface activity
compared to natural lung surfactant. Dynamic surface tension lowering and

adsorption properties of G^E were essentially identical to^those of
freshly isolated bovine wHe surfactant. Thus, hydrophobi^BkP 6-14 is
the only protein detected m bovine lung extract surfactants with full
biophysical activity. (ABSTRACT TRUNCATED AT 250 WORDS)

Lll ANSWER 4 OF 15 MEDLINE

ACCESSION NUMBER: 84203110 MEDLINE

DOCUMENT NUMBER: 84203110 PubMed ID: 6721905

TITLE: Changes in the connective tissue proteins,

glycosaminoglycans and calcium in the arteries of the
cynomolgus monkey during atherosclerotic induction and
regression.

AUTHOR: Hollander W; Colombo M; Faris B; Franzblau C; Schmid K;

Wernli M; Bernasconi U
CONTRACT NUMBER: HL-132 62 (NHLBI)

SOURCE: ATHEROSCLEROSIS, (1984 Apr) 51 (1) 89-108.

Journal code: 0242543. ISSN: 0021-9150.
PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE : Eng 1 i s h

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198406

ENTRY DATE: Entered STN : 19900319

Last Updated on STN: 19970203
Entered Medline: 19840621
AB The chemical ***composition*** of the aorta, carotid, coronary and
cerebral arteries of the cynomolgus monkey was determined during the
induction and 'regression' of atherosclerosis. The feeding of a 2%
cholesterol and 10% butter diet for 6 months resulted in extensive and
severe atherosclerosis involving the aorta, carotid and coronary arteries.
The involvement of these vessels was reflected by increases in arterial
weight and chemical content of cholesterol, ***collagen*** , elastin,

★★★glycosaminoglycans*** (GAGs) and calcium. The cerebral arteries,
which showed no atherosclerotic involvement, likewise showed no
significant changes in weight and ** Composition*** . During the
12 -month regression period marked changes in the chemical

***composition*** of the involved arteries occurred and these included
further increases in the ***collagen*** , GAG and calcium content of
the vessels and decreases in the free and esterified cholesterol content.
These changes were consistent with the gross and microscopic findings
which revealed that during regression the pre-established lesions had not
decreased in size but had become more fibrotic and calcified while the
number of foam cells and amount of lipid contained in the lesion had
decreased. During induction and regression, much of the cholesterol
contained in the involved vessels appeared to be present in a crystalline
form as indicated by the appearance of cholesterol clefts in the lesions.
Aortic ***collagen*** was not altered with respect to ***amino***

***acid*** ***composition*** and behavior in acrylamide gels

throughout the study. However, elastin prepared by hot alkali

***treatment*** from diseased vessels, showed minor changes in

***amino*** ***acids*** during induction and marked changes during

regression presumably due to the binding of ***glycoproteins*** to the
elastin. The GAG ***composition*** of the involved arteries did not
change during induction, whereas during regression the percent dermatan
sulfate increased while the percent of heparan sulfate decreased. The
over-all findings are consistent with the concept that the interaction of
the connective tissue proteins with the GAGs, ** lipoproteins*** and
calcium of the artery plays an important role in the development and
regression of advanced atherosclerotic disease.

Lll ANSWER 5 OF 15 MEDLINE
ACCESSION NUMBER: 83108655 MEDLINE
DOCUMENT NUMBER: 83108655 PubMed ID: 6130060

TITLE: Properties of pili from Escherichia coli SS142 that mediate

mannose-resistant adhesion to mammalian cells.
AUTHOR: Mett H; Kloetzlen L; Vosbeck K

SOURCE: JOURNAL OF BACTERIOLOGY, (1983 Feb) 153 (2) 1038-44.

Journal code: 2985120R. ISSN: 0021-9193.
PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE : English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 1983 03

ENTRY DATE: Entered ST^pi9900318

Last Updated on STN : 19950206

Entered Medline: 19830317
AB We isolated pili from Escherichia coli SS142 . These pili had a diameter of
6 nm and an average length of 400 nm. They were composed of subunits with
a molecular weight of 18,000. Their ***amino*** ***acid***

***composition*** was determined; ***methionine*** and proline were
not detected. The isolated pili retained mannose-resistant
hemagglutinating activity. Proteolytic digestion and glutaraldehyde
fixation led to partial or complete loss of the hemagglutinating activity
of the pili without causing any detectable damage to their supramolecular
structure, which was only disintegrated by ***treatment*** with hot
sodium dodecyl sulfate. The hemagglutinating activity of E. coli SS142 was
inhibited by the ***glycoproteins*** fetuin and Tamm-Horsf all protein,
as well as by the ***glycolipids*** phytyl lactoside,

dansyl-sphingosine lactoside, and digalactosyl diglyceride. Isolated pili
inhibited the adhesion of the homologous strain E. coli SS142 to Intestine
407 cell monolayers, but did not inhibit the adhesion of E. coli strain
B-413, B-506, or 2699. This indicates that E. coli SS142 binds to a
receptor different from those recognized by the other strains and that
mannose-resistant adhesion to tissue culture cells can be classified into
different subtypes .

Lll ANSWER 6 OF 15 MEDLINE
ACCESSION NUMBER: 80153659 MEDLINE
DOCUMENT NUMBER: 80153659 PubMed ID: 7362702

TITLE: Characterization and properties of a lipoprotein-complexing

proteoglycan from human aorta.
AUTHOR: Camejo G; Lalaguna F; Lopez F; Starosta R

SOURCE: ATHEROSCLEROSIS, (1980 Mar) 35 (3) 307-20.

Journal code: 0242543. ISSN: 0021-9150.
PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198005

ENTRY DATE: Entered STN: 19900315

Last Updated on STN: 19900315
Entered Medline: 19800530
AB The preparation of a ***proteoglycan*** (PG) from human aortic
intima-media is described. The PG was obtained from intima-media
homogenates by differential centrif ugation, exclusion chromatography and
preparative agarose electrophoresis. Crude or purified preparations of the

***proteoglycan*** are capable of forming specific insoluble complexes
with LDL, purified or in serum. This product has been labelled

***lipoprotein*** -complexing ***proteoglycan*** (LCP-3) . On agarose
and cellulose acetate electrophoresis LCP-3 appears as a single band.
However, its ***glycosaminoglycan*** (GAG) moiety shows a

***composition*** and chromatographic behaviour compatible with hybrid
or mixed chains of chondroitin-6-so4 , dermatan sulfate and heparin and/or
heparan sulfate. The specificity of LCP-3 for LDL disappears when it is

***treated*** .with testicular hyaluronidase or proteolytic enzymes.
Ionic strength, pH, Ca++ and Mg++ modulate the amount of LDL
insolubilized. The ***amino*** ***acid*** ** Composition*** of

the protein from LCP-3 is that of a basic protein (s), perhaps bound
covalently through xylose-- ***serine*** residues to the GAG's. The
estimated molecular weight of LCP-3 is 1 to 5 x 10(6) daltons . The
presence of LCP-3 to intima-media and its specificity for interacting with
LDL at conditions near to physiological ones are suggestive of the role
that this type of structure may play in the association of the atherogenic

***lipoproteins*** with components of the arterial intima-media.

Lll ANSWER 7 OF 15 MEDLINE
ACCESSION NUMBER: 76136332 MEDLINE
DOCUMENT NUMBER: 76136332 PubMed ID: 56198

TITLE: Studies on the isolation and partial characterization of

apolipoprotein D and lipoprotein D of human plasma.
AUTHOR: McConathy W J; Alaupovic P

SOURCE: BIOCHEMISTRY, (1976 Feb 10) 15 (3) 515-20.

Journal code: 0370623 . ISSN: 0006-2960 .
PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; A^^le; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 197606

ENTRY DATE: Entered STN: 19900313

Last Updated on STN: 19900313
Entered Medline: 19760602
AB This report describes further studies on the characterization of
apolipoprotein D (ApoD) , a recently recognized human plasma
apolipoprotein, and presents results on the isolation and distribution of
its ***lipoprotein*** form, ***lipoprotein*** D (LP-D) . ApoD,
isolated by a procedure combining hydroxylapatite and Sephadex G-100
column chromatography, migrated on 7% polyacrylamide gel as a single band
with a mobility intermediate between those of A- II and C-II polypeptides.
On double diffusion and Immunoelectrophoresis, ApoD reacted only with
antiserum to ApoD. It was characterized by the presence of all common

***amino*** ***acids*** including half- ***cystine*** . The amino

terminal acid was blocked. Carbohydrate analysis demonstrated that ApoD is
a ***glycoprotein*** with glucose, mannose, galactose, glucosamine,
and sialic acid accounting for 18% of the dry weight of ApoD. The
estimated molecular weight of ApoD IS 22 100. ApoD occurs in the serum as
a ***lipoprotein*** which was isolated from high density lipoproteins3
by two different chromatographic procedures. In the first procedure, high
density lipoproteins3 were ***treated*** with neuraminidase and
chromatographed on concanavlin A. The retained fraction containing LP-D
was purified by hydroxylapatite column chromatography. Alternatively, LP-D
was isolated by a procedure combining chromatography of high density
lipoproteins3 or whole serum on an immunosorber containing antibodies to
ApoD, and hydroxylapatite column chromatography. LP-D displayed a single,
symmetrical boundary in the analytical ultracentrif uge and a single band
on 7% polyacrylamide gel electrophoresis. When injected into rabbits it
produced antisera that reacted only with ApoD. On Immunoelectrophoresis
LP-D had a mobility different from that of ***lipoprotein*** A (LP-A) .
A direct immunological comparison of LP-D and LP-A showed a reaction of
nonidentity. LP-D consists of 65-75% protein and 25-35% lipid. The lipid
moiety contains cholesterol, cholesterol ester, triglyceride, and

★★★phospholipid*** . The ★★★phospholipid*** . ***composition*** is
characterized by a relative high content of lysolecithin and sphingomyelin
and a relatively low content of lecithin. We have concluded from these
studies that ApoD is a unique apolipoprotein that exists in the form of a
distinct ★★★lipoprotein*** family with a macromolecular distribution
extending from very low density ***lipoproteins*** into very high
density ***lipoproteins*** , but with a maximum concentration in high
density lipoproteins3 and a minimum concentration in high density

* * * 1 ipoprot e ins * * *

Lll ANSWER 8 OF 15 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:809107 CAPLUS

DOCUMENT NUMBER: 132:40301

TITLE: A new cosmetic solution for a mild to moderate xerosis

AUTHOR (S) : Morganti, P.; Fabrizi, G.; James, B.

CORPORATE SOURCE: R. and D - Mavi Sud S.r.l., Aprilla, 04011, Italy

SOURCE: Journal of Applied Cosmetology (1999), 17(3), 86-93

CODEN: JACOEL; ISSN: 0392-8543
PUBLISHER: International Ediemme

DOCUMENT TYPE: Journal
LANGUAGE : Engl i sh

AB As it is known, ceramides, together with cholesterol and fatty acids

making up the lamellar layers, play a key role in maintaining balanced the
lipid barrier of the skin. PCA, a fundamental agent of the NMF (Natural
Moisturizing Factors) , and ★★★glycine*** , the main component of

***collagen*** , behave as "cutaneous sponges" able to hold water for a
long time at the deep cutaneous level . Hyaluronic acid and some
chitosan-derivs . , contribute to cutaneous superficial hydration, acting
both as topical protectors and as active principles able to hold high
quantities of water. Based on the aforementioned facts, the hydrating
activity of a special multilamellar ***compn*** .'based on

★★★phospholipids*** , ceramide-6 and phytosphingosine enriched with
hyaluronic acid, a chitosan deriv., vitamin C, PCA, ** *glycine*** and
arginine was studied. The study was a randomized double -blind
placebo-controlled study, carried out at two dermatol . offices on 40 very
dry skinned female volunteers aged 23-3 5. The product activity was

j ^Jfchod and by measuring hydra tior^anc
lJBg the 3C System (Dermotech, Rom^P Italy) for a

measured by a clin. score
superficial skin lipids us

three month period. Skin tolerability was also controlled. This 12 -wk
study, has shown the multi-lamellar ***compn*** . to be significantly
superior to placebo in the ***treatment*** of mild to severe xerosis.
In fact, both the hydration and the surface lipids increased quickly on
the area ***treated*** from 70% to 80% (p<0.005). Moreover, there was
a significant correlation (r=0.94) between the results recorded by the
clin. score method and these obtained by the 3C System. The product was
generally well tolerated and no side effects were detected during the
study.

REFERENCE COUNT:

2 0 THERE ARE 2 0 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Lll ANSWER 9 OF 15 CAPLUS COPYRIGHT 2 002 ACS

ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE :

INVENTOR (S) :
PATENT ASSIGNEE (S) :
SOURCE :

DOCUMENT TYPE:
LANGUAGE :

FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:

1995 : 538559 CAPLUS
122 :274034

Immunomodulating compositions from bile

Rang, Romeo

Imutec Corp., Can.

PCT Int. Appl. , 165 pp.

CODEN : PIXXD2

Patent

English

1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

WO 9507089

W:

AM, AT,
GB, GE,

MW,
UZ
MW,
PT,

Al

19950316

MN,
US,
RW: KE,
NL,

CA 2171281

AU 9476489

EP 717631

R: AT, BE,

CN 1136777

JP 09502706

NO 9600907

FI 9601109

AU 9897242

AU 732816
PRIORITY APPLN. INFO.

OTHER SOURCE (S) :
GI

WO 1994-CA494 19940909

AU, BB, BG, BR, BY, CA, CH, CN, CZ , DE, DK, EE, ES, FI ,

HU, JP, KE, KG, KP, KR, KZ , LK, LR, LT, LU, LV, MD, MG,

NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA,

SD, AT, BE, CH,
SE, BF, BJ, CF,
AA 19950316
Al 19950327
Al 19960626
CH, DE, DK, ES,

A

T2

A

A

Al

B2

19961127
19970318
19960430
19960506
19990304
20010503

DE, DK, ES, FR, GB, GR,
CG, CI, CM, GA, GN, ML,
CA 1994-2171281
AU 1994-76489
EP 1994-926737
FR, GB, GR, IE, IT, LI,
CN 1994-194002
JP 1994-508370
NO 1996-907
FI 1996-1109
AU 1998-97242

US 1993-118269 A

US 1993-155303 A

US 1994-231726 A

AU 1994-76489 A3

WO 1994-CA494 W
MARPAT 122 :274034

IE, IT, LU, MC,
MR, NE, SN, TD, TG

19940909

19940909

19940909
LU, MC, NL, PT, SE

19940909

19940909

19960306

19960308

19981221

19930909
19931122
19940424
19940909
19940909

/ Structure 1 in file .gra /

AB A ***compn*** . for use as an immunomodulator comprises small -mol . -wt .
components (<3000 Da) extractable from bile of animals which (a) are
capable of stimulating monocytes and macrophages in vitro; (b) are capable
of modulating tumor necrosis factor prodn. ; (c) contain no measurable
IL-la, IL-lb, TNF, IL-6, IL-8, IL-4, GM-CSF or I FN - . gamma . / (d) have an
anti-prolif erative effect in a malignant mouse hybridoma cell line; (e)
show no cytotoxicity to human peripheral blood mononuclear cells; and (f)
contain no endotoxin. The bile components may include steroids [I; X = H,
OH, :0, OS03H; Y = CHMe (CH2 ) 3R1 , CHMe (CH2 ) 2R2 ; Rl = CHMe2 , CHMeCH20H,
CHMeCHO, C02H; R2 = CH (OH) CHMeC02H, C02H, CONHR; R = ***amino***

***acid*** residue] and their .DELTA. 4, .DELTA. 5(6), and .DELTA. 6
dehydro derivs . , ***phospholipids*** , sphingolipids , diglycerides ,
oligosaccharides, mucin or ***proteoglycan*** hydrolysis products,
fat-sol. vitamins, glutamic acid conjugates, alkylamines, fatty acids,

etc. Thus, bovine gall b3*|der bile was mixed with an equ|^^vol . of EtOH,
centrifuged, optionally ^J*treated*** with activated cUPsncd. by

evapn., and extd. with Et20, and the aq. phase was buffered, autoclaved,
and analyzed by HPLC.

Lll ANSWER 10 OF 15 CAPLUS COPYRIGHT 2 002 ACS
ACCESSION NUMBER: 1977:3246 CAPLUS

DOCUMENT NUMBER: 86:324 6

TITLE: Phospholipids in plasma lipoproteins and cell

membranes : relation to vascular disease
AUTHOR (S) : Jackson, Richard L.

CORPORATE SOURCE: Dep. Med., Baylor Coll. Med., Houston, Tex., USA

SOURCE: Cardiovasc. Res. Cent. Bull. (1973), 11(4), 104-21

CODEN: CRCBAK
DOCUMENT TYPE: Journal
LANGUAGE : Engl i sh

AB The major protein (or apolipoprotein) from human plasma high-d.

***lipoproteins*** has been isolated and shown to contain 2 monomeric
units covalently linked by a single disulfide bond. Based on its
carboxyl -terminal ***amino*** ***acid*** , the protein was

designated apoLP-Gln-II . It contained no histidine, arginine, of
tryptophan. ***Amino*** ***acid*** anal, of reduced-

aminoethylated apoLP-Gln-II indicated 77 residues and a single

***methionine*** per monomeric unit. Two unique cyanogen bromide
fragments, CNBr III and IV, were isolated from the reduced-aminoethylated
protein and accounted for all of the 77 ***amino*** ***acids*** of

the monomer. CNBr IV had 26 residues, a blocked amino-terminus , no

***isoleucine*** , one residue of aminoethylcysteine , carboxyl -terminal
homoserine and corresponded to the amino- terminal and ***cystine***
-contg. portion of apoLP-Gln-II . CNBr III had 51 ***amino***

***acids*** (including one residue of ***isoleucine*** ) ,
carboxyl -terminal glutamine, and no aminoethylcysteine and corresponded to
the carboxyl -terminus of apoLP-Gln-II . ApoLP-Gln-II and the 2 cyanogen
bromide fragments have been tested for their ability to bind phosphatidyl
choline by the iinhibition of the reactivation of delipidated
mitochondrial . beta . -hydroxybutyric dehydrogenase; CNBr III but not CNBr
IV retained the ability to bind phosphatidyl choline. The major

★★★glycoprotein*** from human red cell membranes was isolated and
characterized. The protein contained 200 ***amino*** ***acids*** ,

a mol. wt. of 55,000 and had 60% carbohydrate. ***Treatment*** of the

★★★glycoprotein*** with cyanogen bromide yielded 5 fragments. Three of
these (designated C-l, C-2, and C-5) have been aligned as unique portions
of a single polypeptide chain. C-5 and C-l represented the N- terminal
fragments, in that order, and the 3rd, C-2, was the C-terminal fragment of
the original polypeptide chain. From the ***amino*** ***acid***

***compn*** . and carbohydrate content of C-5, C-l, and C-2 the mol.
could be divided into 3 distinct regions. These were a receptor or
carbohydrate - contg . N- terminal segment, an internal hydrophobic domain of
approx. 30 residues, and a hydrophilic, proline-rich-C-terminal portion.
This unique mol. topoggraphy suggested an amphipathic model for the in
situ orientation of this mol. in which the hydrophobic domain of the

★★★glycoprotein*** lies within the ***phospholipid*** bilayer of the
membrane. A partial ***amino*** ***acid*** sequence of the

hydrophobic domain was reported. These studies suggested that specific

***amino*** ***acid*** sequences are required for

***phospholipid*** binding to sol. and membrane proteins.

Lll ANSWER 11 OF 15 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1971:549294 CAPLUS

DOCUMENT NUMBER: 75:14 92 94

TITLE: Proteins and glycoproteins of hamster kidney

fibroblast (BHK21) plasma membranes and endoplasmic
reticulum

AUTHOR (S) : Gahmberg, Carl G.

CORPORATE SOURCE: Dep. Serol . Bacterid . , Univ. Helsinki, Helsinki,

Finland

SOURCE: Biochim. Biophys . Acta (1971), 249(1), 81-95

CODEN: BBACAQ
DOCUMENT TYPE: Journal
LANGUAGE : Engl i sh

AB Hamster fibroblast plasma membranes and endoplasmic reticulum were

solubilized by Na dodecyl sulfate and 2 -mercaptoethanol ***treatment***

and studied by polyacrylara^fe gel electrophoresis in the pr^ence of Na
dodecyl sulfate. The elec^Rphoretic patterns of plasma me^Pranes and

endoplasmic retculum differed. The ***amino*** ***acid***

***compns*** . of 3 major plasma membrane protein bands differed
significantly. Both membranes contained a fast-moving component of low
apparent mol. wt. (<10,000) in Na dodecyl sulf ate-polyacrylamide gel
electrophoresis. It could be stained with Coomassie Blue and labeled by

***amino*** ***acids*** and glucosamine but not by fucose. It was

probably lipid since its mobility on polyacrylamide gel electrophoresis
corresponded to that of isolated radioactive gangliosides and

***phospholipids*** and quant. ***amino*** ***acid*** anal,

showed it did not contain protein. When cells were labeled with
glucosamine or fucose the labels were 9-12 times more coned, in the plasma
membranes than in the homogenate. The apparent mol. wts. of the major
plasma membrane and endoplasmic reticulum ***glycoproteins*** were
detd. by polyacrylamide gel electrophoresis.

Lll ANSWER 12 OF 15 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1968:457536 CAPLUS

DOCUMENT NUMBER: 69:57536

TITLE: An envelope-specific glycoprotein from Escherichia

coli B

AUTHOR (S) : Okuda, Shinichi; Weinbaum, George

CORPORATE SOURCE: Albert Einstein Med. Center, Philadelphia, Pa., USA

SOURCE: Biochemistry (1968), 7(8), 2819-25

CODEN: B I CHAW
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An envelope-specific ***glycoprotein*** has been isolated from E. coli
B. This ***glycoprotein*** is phenol sol. and accounts for about 10%
of the total cell protein, 35-45% of the total envelope protein, and
50-60% of the partially purified membrane protein. There is about 4%
carbohydrate assocd. with the ***glycoprotein***
N-Acetylglucosamine-14C is rapidly incorporated into the

★★★glycoprotein*** , and the amt. of incorporation is not appreciably
reduced by an excess of ***amino*** ***acids*** in the growth

medium. The ***glycoprotein*** is isolated as a ***phospholipid***
***glycoprotein*** complex. The complex is quant, aggregated in the
presence of 0.02M Mg2+ or Ca2+. Aggregation is dependent upon the
presence of both ***glycoprotein*** and ***phospholipid***

***Amino*** *** ac id*** anal, of the ***glycoprotein*** shows

that aspartic acid and tyrosine are increased relative to the

***amino*** ***acid*** ***compn*** . of isolated envelopes.

Acrylamide gel electrophoresis shows that the ***glycoprotein***
dissoc. in the presence of urea and the multiple -banding pattern is
clearest in acidic conditions. Pronase ***treatment*** of the

★★★glycoprotein*** (labeled with N-acetylglucosamine-14C) produced a
series of labeled glycopeptides which were isolated by Sephadex G-25
filtration and high-voltage electrophoresis. At least one glycopeptide
contains aspartic acid and glucosamine. The exact linkage was not detd.
Inhibitors of protein synthesis such as chloramphenicol or phenethyl ale.
inhibit this ***glycoprotein*** synthesis in vivo. The
envelope-specific ***glycoprotein*** of E. coli B may have antigenic
similarties to beef heart mitochondrial structural protein.

Lll ANSWER 13 OF 15 BIOSIS COPYRIGHT 2 002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1982:238904 BIOSIS
DOCUMENT NUMBER : BA7 4:11384

TITLE: BIOCHEMICAL PROPERTIES OF BIOLOGICALLY ACTIVE FC- GAMMA

RECEPTORS OF HUMAN B LYMPHOCYTES.
AUTHOR (S) : SUZUKI T; TAKI T; HACHIMINE K; SADAS IVAN R

CORPORATE SOURCE: DEP. MICROBIOL., UNIV. KANS . MED. CENT., COLL. HEALTH SCI.

HOSP., RAINBOW BLVD. AT 39TH, KANSAS CITY, KANS. 66103.
SOURCE: MOL IMMUNOL, (1981) 18 (1), 55-66.

CODEN: MOIMD5. ISSN: 0161-5890.
FILE SEGMENT: BA; OLD

LANGUAGE : Engl i sh

AB Biochemical and biological properties of Fc. gamma, receptors isolated from
several different CLL [chronic lymphocytic leukemia] patients cell lysates
were investigated to gain insight into their structure- function
relationship. The Fc. gamma. R proteins isolated in a relatively homogenous
and biologically active form are a single polypeptide chain of MW near

30,000 that starts with an^Miino terminal residue of ***c^^cine***
Extensive reduction and a^pLation did not change their molj^pLty in

SDS-PAGE [sodium dodecyl sulf ate-polyacrylamide gel electrophoresis] ,
behavior during gel filtration, isoelectric points in 6 M urea and

***amino*** ***acid*** ***compositions*** . Their ***amino***

***acid*** ***compositions*** are essentially identical to each

other, and are characterized by 2 readily alkylatable cysteinyl residues.
Fc. gamma. R proteins apparently lack glucosamine and galactosamine, which
are the usual components of ***glycoproteins*** . Tryptic peptide maps
of Fc. gamma. R materials isolated from 3 different CLL patients cell
lysates were nearly identical to each other. The number of typtic peptides
identified by ninhydrin staining were in good agreement with those
expected from the total number of lysyl and arginyl residues estimated by

***amino*** ***acid*** analysis using the assumed MW of 30,000 for

Fc. gamma. R materials. Fc. gamma. R materials appeared to be associated with
a mole of ***phospholipids*** and a mole of free fatty acid per mole
of protein. The ***phospholipids*** associated with Fc. gamma. R
proteins were phosphatidyl -choline, - ***serine*** and -ethanolamine ,
which are the usual components of the plasmsa membrane of mammalian cells.
Their association with Fc. gamma. R proteins seems to be tight, since 70% of
phosphorus associated with Fc. gamma. R protein remained bound after
delipidation and only phospholipase C ***treatment*** released .apprx.
75% of P from Fc. gamma. R. The fatty acids extracted from 2 different
Fc. gamma. R materials were found by gas chromatography to be similar to
each other and were composed of the usual membrane fatty acids (C16:0,
C18:0 and C18:l). One preparation showed the association of a small but
significant amount of arachiodonic acid (C20:4). Delipidation by
chloroform-methanol and phospholipase C ***treatment*** did not affect
the IgG-binding capacity of Fc. gamma. R materials.

Lll ANSWER 14 OF 15 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 81086220 EMBASE
DOCUMENT NUMBER: 1981086220

TITLE: Changes in phospholipid and ganglioside during

differentiation of mouse myeloid leukemia cells.
AUTHOR: Saito M. ; Nojiri H.; Yamada M.

CORPORATE SOURCE: Dept. Biochem., Tokyo Metrop. Inst. Gerontol., Tokyo 173,

Japan

SOURCE: Biochemical and Biophysical Research Communications, (1980)

97/2 (452-462) .

CODEN: BBRCA
COUNTRY: United States

DOCUMENT TYPE: Journal
FILE SEGMENT: 02 5 Hematology

02 9 Clinical Biochemistry

026 Immunology, Serology and Transplantation

LANGUAGE: English

AB When mouse myeloid leukemia Ml cells were induced to differentiate into
macrophages by bacterial lipopolysaccharide (LPS) , ***phospholipids***
and gangliosides of the cells changed markedly. The amounts of
phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol per
mg protein increased 30%, 20% and 30%, respectively, during
differentiation, but the others, phosphatidyl ***serine*** and
sphingomyelin, did not increase significantly. Three species of
gangliosides constituted of major portions of gangliosides in Ml cells.
Several -fold increase in monosialoganglioside GM1 was observed in the LPS-

***treated*** cells with a concomitant decrease in disialogangliosides .
Based upon the ***treatment*** with sialidase, this GM1 was identified
to be GMlb, which was recently found in rat ascites hepatoma cells and
human erythrocyte membranes. It has been reported that mouse myeloid
leukemia Ml cells can be induced to differentiate into macrophages by
various reagents, such as proteins in the conditioned medium of mouse lung
fibroblasts, steroids, polyanions including poly (ADR-Rib) and
lipopolysaccharide. During this induction, differentiation-associated
properties appeared; cell adhesion to culture flask, locomotion,
phagocytosis, Fc- and c3 -receptors , lysozyme and cathepsin D and changes
in cell morphology. Recently Nagata and Ichikawa reported that Fc-receptor
appeared without protein synthesis at an earlier stage of induction of
differentiation. Changes in ***glycoprotein*** of cell membrane in Ml
cells were also observed during the cell differentiation.

★★★Phospholipids*** are major constituents of the cell membrane and
changes in their ** Composition*** might cause changes of the cell

morphology as well as var^^ cellular functions. Gangliosi^^
a small portion of the gl^^R: conjugates of cell surfaces, bu^^iight exhibit
an important function as special receptors or surface markers, providing
negative charges to the cell surface. This work shows that changes in

★★★phospholipids*** and gangliosides of mouse myeloid leukemia Ml cells
were associated with the differentiation of the cells into mature cells.
In addition, evidence is presented that a monosialoganglioside GMlb, which
has been uncommon in biological materials, was identified in Ml cells.

Lll ANSWER 15 OF 15 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 74204783 EMBASE
DOCUMENT NUMBER: 1974204783

TITLE: Studies on human placenta. I. Isolation and partial

characterization of a glycoprotein from the chorionic
villus .

AUTHOR: Schwartz E.S.; Gang N.F.; Gelfand M.M.

CORPORATE SOURCE: Lady Davis Inst. Med. Res., Jew. Gen. Hosp., Montreal,

Canada

SOURCE: American Journal of Obstetrics and Gynecology, (1974) 118/6

(857-863) .

CODEN: AJOGAH
DOCUMENT TYPE: Journal

FILE SEGMENT: 010 Obstetrics and Gynecology

029 Clinical Biochemistry

003 Endocrinology
LANGUAGE: English

AB Recently, the authors were successful in isolating, by physical means, an
insoluble fraction (IF) from the chorionic villi of term human placentas.
The purpose of the present study was to determine the gross chemical

***composition*** , and the solubility properties of the insoluble
fraction. On a dry weight basis, the IF was found to contain 5%

***phospholipid*** , 3.7% bound hexose, 1.4% hexosamines, and 0.6% sialic
acid. On ***amino*** *** ac i c ;*** analysis, the membrane revealed a

high concentration of acidic ***amino*** ***acids*** , no

hydroxyproline or hydroxylysine , and trace amounts of half ***cystine***
and ***methionine*** . Trypsin, as well as mild alkali

***treatment*** , solubilized 50%; urea, 30%; and urea followed by
pronase digestion, 98% of the isolated fraction. It is concluded that the
IF isolated from the chorionic villi is a noncollagen containing lipo

★★★glycoprotein*** , made up of three subcomponents as determined by
acrylamide gel electrophoresis. Since antibodies against the IF showed
localization in the periphery of the chorionic villus in the placenta and
cross reacted with the Bowman's capsule and the glomerular and tubular
basement membranes in the kidney, it is suggested that the

***glycoprotein*** is associated with, or part of, the trophoblast
basement membrane.

=> d his

(FILE 'HOME' ENTERED AT 12:22:03 ON 17 NOV 2002)

FILE 'MEDLINE, CAPLUS , BIOSIS, EMBASE, SCISEARCH, AGRICOLA ' ENTERED AT
12:22:32 ON 17 NOV 2002

LI 2800622 S COMPOSITION

L2 23697 S (PHARMACEUTICAL COMPOSITION) OR (THERAPEUTIC COMPOSITION)

L3 11029 S (EXTRACELLULAR MATRIX) (W) (MATERIAL OR COMPOUND OR COMPONENT

L4 1097283 S GLYCOSAMINOGLYCAN OR COLLAGEN OR CARTILAGE OR ( CHRONDRO I T IN S

L5 758458 S PHOSPHOLIPID OR GLYCOLIPID OR LIPOPROTEIN

L6 2753150 S (AMINO ACID ) OR GLYCINE OR ALANINE OR LEUCINE OR ISOLEUCINE

L7 0 S L2 (P) (L3 OR L4 ) (P) L5 (P) L6

L8 256 S LI (P) (L3 OR L4 ) (P) L5 (P) L6

L9 111 DUPLICATE REMOVE L8 (145 DUPLICATES REMOVED)

L10 0 S L9 (P) (PHARMACEUTICAL OR THERAPEUTIC OR MEDICAMENT)

Lll 15 S L9 (P) TREAT?

=> s (molar ration) (p) 19

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - * AND 1 OPERATOR ASSUMED 'RATION) (P) L92 »

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - 'AND' OPERATOR ASSUMED 'RATION) (P) L94 '

L12 0 (MOLAR RATION) (P) L9

= > s penicillin or caphalospori^ftr cyclosporin or antibiotic or^Pimunosuppressant

L13 103 8986 PENICILLIN OR CAPHALOSPORIN OR CYCLOSPORIN OR ANTIBIOTIC OR
IMMUNOSUPPRESSANT

=> s 16 (p) (molar ratio)

L14 6279 L6 (P) (MOLAR RATIO)

=> S 113 (p) 114

L15 69 L13 (P) L14

=> s 115 (p) (13 or 14) (p) 15

L16 0 L15 (P) (L3 OR L4) (P) L5

=> s mineral or vitamin or antioxidant or (omega-3 oil) or zinc or (zinc oxide)
L17 2126390 MINERAL OR VITAMIN OR ANTIOXIDANT OR (OMEGA-3 OIL) OR ZINC OR
(ZINC OXIDE)

=> d his

(FILE 'HOME' ENTERED AT 12:22:03 ON 17 NOV 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA ' ENTERED AT
12:22:32 ON 17 NOV 2002
LI 2800622 S COMPOSITION

L2 23697 S (PHARMACEUTICAL COMPOSITION) OR (THERAPEUTIC COMPOSITION)

L3 1102 9 S (EXTRACELLULAR MATRIX) (W) (MATERIAL OR COMPOUND OR COMPONENT

L4 1097283 S GLYCOSAMINOGLYCAN OR COLLAGEN OR CARTILAGE OR ( CHRONDRO I T IN S

L5 758458 S PHOSPHOLIPID OR GLYCOLIPID OR LIPOPROTEIN

L6 2753150 S (AMINO ACID ) OR GLYCINE OR ALANINE OR LEUCINE OR ISOLEUCINE

L7 0 S L2 (P) (L3 OR L4 ) (P) L5 (P) L6

L8 256 S LI (P) (L3 OR L4 ) (P) L5 (P) L6

L9 111 DUPLICATE REMOVE L8 (145 DUPLICATES REMOVED)

L10 0SL9(P) (PHARMACEUTICAL OR THERAPEUTIC OR MEDICAMENT)

Lll 15 S L9 (P) TREAT?

L12 0 S (MOLAR RATION) (P) L9

L13 1038986 S PENICILLIN OR CAPHALOSPORIN OR CYCLOSPORIN OR ANTIBIOTIC OR I

L14 6279 S L6 (P) (MOLAR RATIO)

L15 69 S L13 (P) L14

L16 0 S L15 (P) (L3 OR L4) (P) L5

L17 212 63 90 S MINERAL OR VITAMIN OR ANTIOXIDANT OR (OMEGA-3 OIL) OR ZINC OR

=> s 19 (p) 117

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - 'AND 1 OPERATOR ASSUMED »L140 (P) L129'

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - 'AND 1 OPERATOR ASSUMED 'L142 (P) L130'

L18 5 L9 (P) L17

=> d 118 1-5 ibib abs

LI 8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2 002 ACS
ACCESSION NUMBER: 1999:809107 CAPLUS

DOCUMENT NUMBER: 132:40301

TITLE: A new cosmetic solution for a mild to moderate xerosis

AUTHOR (S) : Morganti, P.; Fabrizi, G. ; James, B.

CORPORATE SOURCE: R. and D - Mavi Sud S.r.l., Aprilla, 04011, Italy

SOURCE: Journal of Applied Cosmetology (1999), 17(3), 86-93

CODEN: JACOEL; ISSN: 0392-8543
PUBLISHER: International Ediemme

DOCUMENT TYPE: Journal
LANGUAGE: English

AB As it is known, ceramides, together with cholesterol and fatty acids

making up the lamellar layers, play a key role in maintaining balanced the
lipid barrier of the skin. PCA, a fundamental agent of the NMF (Natural
Moisturizing Factors) , and ***glycine*** , the main component of

***collagen*** , behave as "cutaneous sponges" able to hold water for a
long time at the deep cutaneous level. Hyaluronic acid and some
chitosan-derivs . , contribute to cutaneous superficial hydration, acting
both as topical protectors and as active principles able to hold high
quantities of water. Based on the aforementioned facts, the hydrating
activity of a special multilamellar ***compn*** . based on

* * *phosphol ipids * * *

mide-6 and phytosphingosine erjjj^hed with

hyaluronic acid, a chitos^H^leriv. , ***vitamin*** C, P

★★★glycine*** and arginine was studied. The study was a randomized
double-blind placebo-controlled study, carried out at two dermatol .
offices on 40 very dry skinned female volunteers aged 23-35. The product
activity was measured by a clin. score method and by measuring hydration
and superficial skin lipids using the 3C System (Dermotech, Rome, Italy)
for a three month period. Skin tolerability was also controlled. This
12 -wk study, has shown the multi-lamellar ***compn*** . to be
significantly superior to placebo in the treatment of mild to severe
xerosis. In fact, both the hydration and the surface lipids increased
quickly on the area treated from 70% to 80% (p<0.005). Moreover, there
was a significant correlation (r=0.94) between the results recorded by the
clin. score method and these obtained by the 3C System. The product was
generally well tolerated and no side effects were detected during the
study.

REFERENCE COUNT: 2 0 THERE ARE 2 0 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LI 8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2 002 ACS

ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE :

INVENTOR (S) :

PATENT ASSIGNEE (S) :
SOURCE :

DOCUMENT TYPE:
LANGUAGE :

FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:

1996:137694 CAPLUS
124 :173429

Adjuvant compositions comprising a mineral salt and
another immunostimulating compound
Kandil, Ali; James, Olive A./ Chong, Pele; Klein,
Michel H.

Cannaught Laboratories Ltd., Can.

PCT Int. Appl.

CODEN: PIXXD2

Patent

English

1

54 pp.

PATENT NO.

KIND

DATE

WO

9534308

A2

19951221

WO

9534308

A3

19960523

W: AM,

AT,

AU, BB,

BG, BR,

GB,

GE,

HU, JP,

KE , KG ,

MN,

MW,

NO, NZ,

. PL, PT,

UZ,

VN

RW: KE,

MW,

SD, SZ,

. UG, AT,

LU,

MC,

NL, PT,

, SE, BF,

SN,

TD,

TG

US

5837250

A

19981117

CA

2192659

AA

19951221

AU

9526670

Al

19960105

EP

765163

A2

19970402

R: AT,

BE,

CH, DE,

DK, ES,

US

6290971

Bl

20010918

PRIORITY APPLN.

INFO

APPLICATION NO.

DATE

WO 1995-CA359

19950615

BY,
KP,
RO,

BE,
BJ,

CA,
KR,
RU,

CH,
CF,

CH,
KZ,
SD,

DE,
CG,

CN,
LK,
SE,

DK,
CI,

CZ,
LR,
SI,

ES,
CM,

DE,
LT,
SK,

FR,
GA,

DK,
LU,
TJ,

GB,
GN,

EE,
LV,
TT,

GR,
ML,

ES,
MD,
UA,

IE,
MR,

FR,

US 1995-483856
CA 1995-2192659
AU 1995-26670
EP 1995-921672
GB, GR, IE, IT, LI,
US 1997-750624

19950607
19950615
19950615
19950615
LU, MC,
19970226
19940616
19950615

FI,
MG,
US,

IT,
NE,

NL, PT, SE

OTHER SOURCE
AB Ad j uvant

US 1994-261194 A
WO 1995-CA359 W
(S) : MARPAT 124:173429

***compns*** . for modulating an immune response to an antigen
administered to a host comprise a ***mineral*** salt adjuvant and at
least one other adjuvant. The ***compns*** . provide an adjuvanting
effect on an antigen which is greater than the adjuvanting effect
attainable by one of the adjuvants alone. An antigen is covalently bonded
to a ***glycolipid*** analog to provide a discrete mol . which exhibits
an enhanced adjuvanting effect on the antigen which is greater than the
adjuvanting effect attainable in the absence of such covalent bonding.
The antigen is microbial pathogens, bacteria, viruses, proteins,

★★★glycoproteins*** , ***lipoproteins* ** , peptides, glycopeptides ,
toxoids, carbohydrates, tumor-specific antigens, etc. In example,
synthetic peptides were prepd. as antigen, and N- (2-L- ***leucine***
-amino-2-deoxy- .beta. -D-glucopyranosyl) -N-octadecyldodecanamide acetate,
tripalmityl-Cys-Ser-Ser-Asn-Ala, tripalmityl-Cys -Ser-Glu-Glu-Glu-Glu,
tripalmityl-Cys-Ser-Lys-Lys-Lys-Lys, etc. were prepd. as adjuvant.
Formulations contg. these synthetic antigen and adjuvants were prepd. as
vaccines for HIV, flu, RSV, PIV3, flu BHA, pertussis toxoid, etc.

L18 ANSWER 3 OF 5
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE :

INVENTOR (S) :
PATENT ASSIGNEE (S) :
SOURCE :

DOCUMENT TYPE:
LANGUAGE :

FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:

CAPLUS CO
1995

GHT 2 002 ACS
5 9 CAPLUS
122 :274034

Immunomodulating compositions from bile
Rang , Romeo
Imutec Corp., Can.

PCT Int. Appl.

CODEN: PIXXD2

Patent

English

1

165 pp.

PATENT NO.

KIND DATE

APPLICATION NO. DATE

WO

o c r\ H A O Q

Al

1995 0 j 16

T*T . 7\M

W : AM ,

AT,

AU , on t

"□/"» T3T3

GB,

GE,

HU, JP,

KE , KG,

MN,

MW,

NL, NO,

NZ, PL,

US,

UZ

RW: KE,

MW,

SD, AT,

BE, CH,

NL,

PT,

SE, BF,

BJ, CF,

CA

2171281

AA

19950316

AU

9476489

Al

19950327

EP

717631

Al

19960626

R: AT,

BE,

CH, DE,

DK, ES,

CN

1136777

A

19961127

JP

09502706

T2

19970318

NO

9600907

A

19960430

FI

9601109

A

19960506

AU

9897242

Al

19990304

AU

732816

B2

20010503

PRIORITY APPLN.

INFO

WO 1994-CA494

19940909

OTHER SOURCE (S)
GI

DE, DK, ES, FR, GB, GR,
CG, CI, CM, GA, GN, ML,
CA 1994-2171281
AU 1994-76489
EP 1994-926737
FR, GB, GR, IE, IT, LI,
CN 1994-194002
JP 1994-508370
NO 1996-907
FI 1996-1109
AU 1998-97242

US 1993-118269 A

US 1993-155303 A

US 1994-231726 A

AU 1994-76489 A3

WO 1994-CA494 W
MARPAT 122 : 274034

IE, IT, LU, MC,
MR, NE, SN, TD, TG

19940909

19940909

19940909
LU, MC, NL, PT, SE

19940909

19940909

19960306

19960308

19981221

19930909
19931122
19940424
19940909
19940909

/ Structure 2 in file .gra /

AB A ***compn*** . for use as an immunomodulator comprises small -mol . -wt .
components (<3000 Da) extractable from bile of animals which (a) are
capable of stimulating monocytes and macrophages in vitro; (b) are capable
of modulating tumor necrosis factor prodn. ; (c) contain no measurable
IL-la, IL-lb, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-. gamma.; (d) have an
anti-prolif erative effect in a malignant mouse hybridoma cell line; (e)
show no cytotoxicity to human peripheral blood mononuclear cells; and (f)
contain no endotoxin. The bile components may include steroids [I; X = H,
OH, :0, OS03H; Y = CHMe (CH2 ) 3R1 , CHMe (CH2 ) 2R2 ; Rl = CHMe2 , CHMeCH20H,
CHMeCHO , C02H; R2 = CH (OH) CHMeC02H, C02H, CONHR; R = ***amino***

***acid*** residue] and their .DELTA. 4, .DELTA. 5 (6), and .DELTA. 6
dehydro derivs . , ***phospholipids*** , sphingolipids , diglycerides ,
oligosaccharides, mucin or ***proteoglycan*** hydrolysis products,
fat-sol. ***vitamins*** , glutamic acid conjugates, alkylamines, fatty
acids, etc. Thus, bovine gall bladder bile was mixed with an equal vol.
of EtOH, centrifuged, optionally treated with activated C, coned, by
evapn., and extd. with Et20, and the aq. phase was buffered, autoclaved,
and analyzed by HPLC.

L18 ANSWER 4 OF !
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE :

AUTHOR (S) :
CORPORATE SOURCE:
SOURCE :

CAPLUS COPYRIGHT 2 0 02 ACS
1968:47555 CAPLUS
68 :47555

Lipids of mineralizing epiphyseal tissues in the
bovine fetus
Wuthier, Roy E.

Forsyth Dental Center, Boston, Mass., USA
J. Lipid Res. (1968), 9(1), 68-78
CODEN: JLPRAW

DOCUMENT TYPE: Journa

LANGUAGE : Eng 1 i sW

AB Because lipids had been consistently detected histol. at sites of new

calcification, the lipids of epiphyseal ***cartilage*** and bone in
various stages of mineralization were examd. Lipids were extd. before and
after demineralization and analyzed. Lipid content increased during
proliferation and calcification of epiphyseal ***cartilage*** . Much
less was seen in the adjacent cancellous bone; this corroborates
histochem. findings. Similar ***phospholipid*** ***compns***
were seen in the total lipids of ***cartilage*** and bone. Neutral
(dipolar) ***phospholipids*** accounted for nearly 90% of the total
lipid P and were almost completely extd. before demineralization.

★★★Serine*** - and inositol-contg. ***phospholipids*** and 2 other,
unidentified, acidic lipids could not be effectively extd. from calcifying
tissues until after demineralization. Since the extn. of the acidic
lipids was closely related to the degree of mineralization, it is possible
that they form part of a ***lipoprotein*** - ***mineral*** complex
in the calcifying matrix. Lysophospholipids were detected in all exts . ,
but primarily in those made after decalcification. Acidic lipids are
mainly responsible for the sudanophilia detected histol. at sites of new
calcification. 41 references.

L18 ANSWER 5 OF 5 BIOSIS COPYRIGHT 2 0 02 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1979:149998 BIOSIS
DOCUMENT NUMBER: BA67: 2 9998

TITLE: CHANGES IN CHEMICAL COMPOSITION BIOSYNTHESIS AND STRUCTURE

OF MESOGASTRIC ZONE SECRETION IN CHICKS WITH A
AVITAMINOSIS.

AUTHOR (S) : DUSHEIKO A A; KHOMUTOVSKII 0 A; BLAZHEVICH M A; SOLODOVA E

V; CHERNUKHINA L A; ZABELLO E M
CORPORATE SOURCE: A.V. PALLADIN INST. BIOCHEM. , ACAD. SCI. UKR. SSR, KIEV,

USSR.

SOURCE: UKR BIOKHIM ZH, (1978) 50 (3), 325-331.

CODEN: UBZHD4 . ISSN: 0201-8470.
FILE SEGMENT: BA; OLD

LANGUAGE : Ru s s i an

AB In the intermediate area of the chicken stomach with A-avitaminosis , the
amount of the secretion increased and its chemical ***composition***
changed sharply: the content of water, lipids, hexolamines and sulfates
decreased. By using 14-C-acetate, 35S- ***methionine*** and
35S-sulfate, it was established that renewal of the secretion was
inhibited. EM examinations showed that the secretion was normally
homogenous but with A-avitaminosis it acquired a honeycomb structure, its
physicochemical properties being changed; it became rigid, cuticle-like.
As a result there appeared deep cracks reaching mucosa, which led to
formation of erosions and ulcers . The initial disturbances of the
secretion may not be related to the protein component (as the ratio of

***amino*** ***acids*** in it was almost unchanged) but may depend

on the carbohydrate and lipid components. The hypothesis of de Luck et al .
as to the transport and intermediatory function of ***vitamin*** A in
biosynthesis of ***glycosaminoglycans*** , ***glycolipids*** and
glycolipoproteins was questioned. ***Vitamin*** A may take part in
these processes but not as an intermediate of metabolic systems but at the
level of biological structures (for instance, the Golgi apparatus and
others) which organize these systems and coordinate their function.

=> d his

(FILE ' HOME 1 ENTERED AT 12:22:03 ON 17 NOV 2002)

FILE 1 MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA 1 ENTERED AT
12:22:32 ON 17 NOV 2002

LI 2800622 S COMPOSITION

L2 23697 S (PHARMACEUTICAL COMPOSITION) OR (THERAPEUTIC COMPOSITION)

L3 11029 S (EXTRACELLULAR MATRIX) (W) (MATERIAL OR COMPOUND OR COMPONENT

L4 10972 83 S GLYCOSAMINOGLYCAN OR COLLAGEN OR CARTILAGE OR ( CHRONDRO I T I N S

L5 758458 S PHOSPHOLIPID OR GLYCOLIPID OR LIPOPROTEIN

L6 2753150 S (AMINO ACID ) OR GLYCINE OR ALANINE OR LEUCINE OR ISOLEUCINE

L7 0 S L2 (P) (L3 OR L4 ) (P) L5 (P) L6

L8 256 S LI (P) (L3 OR L4 ) (P) L5 (P) L6

L9 111 DUPLICATE REMOVE L8 (14 5 DUPLICATES REMOVED)

LIO
Lll

0
15

S
S

L9 (P) (PHARI^fcUTICAL OR THERAPEUTIC OR MEDIC^ENT)
L9 (P) TREAT"^^

L12

0

S

(MOLAR RATION) (P) L9

L13

1038986

S

PENICILLIN OR CAPHALOSPORIN OR CYCLOSPORIN OR ANTIBIOTIC OR I

L14

6279

S

L6 (P) (MOLAR RATIO)

L15

69

S

L13 (P) L14

L16

0

S

L15 (P) (L3 OR L4) (P) L5

L17

2126390

S

MINERAL OR VITAMIN OR ANTIOXIDANT OR (OMEGA- 3 OIL) OR ZINC OR

L18

5

S

L9 (P) L17

=> log y

COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR
CA SUBSCRIBER PRICE

QUALIFYING ACCOUNTS )

SINCE FILE TOTAL

ENTRY SESSION

136.31 136.52

SINCE FILE TOTAL

ENTRY SESSION

-5.58 -5.58

STN INTERNATIONAL LOGOFF AT 12:36:14 ON 17 NOV 2002